Cetuximab and Irinotecan in Treating Patients With Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as cetuximab, can locate tumor cells and either kill
them or deliver tumor-killing substances to them without harming normal cells. Drugs used in
chemotherapy use different ways to stop tumor cells from dividing so they stop growing or
die.
PURPOSE: Phase II trial to study the effectiveness of cetuximab and irinotecan in treating
patients who have advanced colorectal cancer that has not responded to previous treatment.